Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma

Journal of Clinical Oncology

Volumn 36, Issue 17, 2018, Pages 1658-1667

  Chesney, Jason ^a   Puzanov, Igor ^b   Collichio, Frances ^d   Singh, Parminder ^e   Milhem, Mohammed M ^f   Glaspy, John ^g   Hamid, Omid ^h   Ross, Merrick ^j   Friedlander, Philip ^c   Garbe, Claus ^k   Logan, Theodore F ^m   Hauschild, Axel ^l   Lebbé, Celeste ⁿ   Chen, Lisa ⁱ   Kim, Jenny J ⁱ   Gansert, Jennifer ⁱ   Andtbacka, Robert H I ^o   Kaufman, Howard L ^p  

^a University of Louisville School of Medicine   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Angeles Clinic and Research Institute   (United States)

ⁱ AMGEN INC   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^l UNIVERSITY OF KIEL   (Germany)

^m INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^o UNIVERSITY OF UTAH   (United States)

^p RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; ONCOLYTIC VIRUS; TALIMOGENE LAHERPAREPVEC; ANTINEOPLASTIC AGENT; B RAF KINASE; BIOLOGICAL PRODUCT; BRAF PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHILL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE PAIN; INTESTINE INJURY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; HUMAN ALPHAHERPESVIRUS 1; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL PRODUCTS; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGRESSION-FREE SURVIVAL; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; YOUNG ADULT;

EID: 85045068631     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.73.7379     Document Type: Article

References (23)

1. Antonia SJ, Larkin J, Ascierto PA: Immuno-oncology combinations: A review of clinical experience and future prospects. Clin Cancer Res 20: 6258-6268, 2014
2. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34, 2015
3. Postow MA, Chesney J, Pavlick AC, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-2017, 2015
4. YERVOY, ipilimumab. Bristol-Myers Squibb, Princeton, NJ, 2015
5. Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
6. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
7. IMLYGIC, talimogene laherparepvec. Amgen, Thousand Oaks, CA, 2015
8. Andtbacka RH, Kaufman HL, Collichio F, et al: Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780-2788, 2015
9. Kohlhapp FJ, Kaufman HL: Molecular pathways: Mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res 22:1048-1054, 2016
10. Subudhi SK, Aparicio A, Gao J, et al: Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci USA 113:11919-11924, 2016
11. Puzanov I, Milhem MM, Minor D, et al: Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 34:2619-2626, 2016
12. Hoffner B, Iodice GM, Gasal E: Administration and handling of talimogene laherparepvec: An intralesional oncolytic immunotherapy for melanoma. Oncol Nurs Forum 43:219-226, 2016
13. Chen DS, Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity 39: 1-10, 2013
14. Wolchok JD, Hoos A, O’Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
15. Fleiss JL, Tytun A, Ury HK: A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 36:343-346, 1980
16. Clopper CJ, Pearson ES: The use of confidence and fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
17. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
18. Wolchok J, Chiarion-Sileni V, Gonzalez R, et al: Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol 34, 2016 (suppl; abstr 9505)
19. Andtbacka RH, Ross M, Puzanov I, et al: Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol 23:4169-4177, 2016
20. Johnson DB, Balko JM, Compton ML, et al: Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749-1755, 2016
21. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma version 1.2017. Fort Washington, PA, 2017
22. Long GV, Dummer R, Ribas A, et al: Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol 34, 2016 (suppl; abstr 9568)
23. Long GV, Dummer R, Ribas A, et al: Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec and pembrolizumab for unresectable stage IIIB-IV melanoma, 12th International Congress of the Society for Melanoma Research. San Francisco, CA, November 18-21, 2015